Erythropoietin and the truths of science

Journal of Nephrology

Volumn 24, Issue 5, 2011, Pages 564-568

  Buemi, Michele ^a   Campo, Susanna ^a   Cernaro, Valeria ^a   Donato, Valentina ^a   Lacquaniti, Antonio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Anemia; Cancer; Erythropoietin; Renal failure

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; BLOOD TRANSFUSION; BLOOD VISCOSITY; BRAIN ISCHEMIA; CARCINOGENESIS; CHRONIC KIDNEY FAILURE; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; ERYTHROPOIESIS; FOOD AND DRUG ADMINISTRATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MORTALITY; NEUROPROTECTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; RENAL PROTECTION; REVIEW; THROMBOEMBOLISM; UNITED STATES;

ANEMIA; CARDIOVASCULAR DISEASES; HEMATINICS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 80052668051     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.5971     Document Type: Review

References (44)

1. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents: time for a reevaluation. N Engl J Med. 2010;362:189-192.
2. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82:7580-7585.
3. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-78.
4. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-1416.
5. Buemi M, Allegra A, Aloisi C, et al. The circadian rhythm of erythropoietin in subjects with pre-terminal uremia. Clin Nephrol. 1992;37:159-160.
6. Buemi M, Allegra A, Laganà A, et al. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients. Riv Eur Sci Med Farmacol. 1993;15:195-197.
7. Drueke TB. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16:S25-S28.
8. Korzeniewska-Dyl I, Wróblewski K, Majewska E, Moczulski D. The effect of uremia and hemodialysis on caspase-1 and caspase-3 activity in neutrophils. J Nephrol. 2010;23:425-430.
9. Leaders FE, Dixon RL, Osborne JW, Long JP. Erythropoietic stimulating factor (ESF) as a stimulant of tumor growth. Proc Soc Exp Biol Med. 1962;110:436-440.
10. Leaders FE, Werder AA, Schmidt C. Erythropoietic stimulating factor (ESF) as a stimulant of cell growth in vitro. Proc Soc Exp Biol Med. 1964;115:658-660.
11. Leaders FE, Werder AA, Schmidt C, Castro ML. Erythropoietic stimulating factor (ESF) associated with an oncogenic virus-host system in vitro. Proc Soc Exp Biol Med. 1965;120:599-604.
12. Leaders FE. Erythropoietic stimulating factor (ESF) in blood from humans with cancer and animals with Novikoff hepatomas. Cancer. 1965;18:496-499.
13. Thorling EB. On the effect of erythropoietin as an accelerant of tumour-growth. Acta Pathol Microbiol Scand. 1965;65:481-492.
14. Ribatti D. Erythropoietin and cancer, a double-edged sword. Leuk Res. 2009;33:1-4.
15. Sturiale A, Campo S, Crascì E, et al. Erythropoietin and its lost receptor. Nephrol Dial Transplant. 2007;22:1484-1485.
16. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264:405-432.
17. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol. 2010;23:369-376.
18. Van der Putten K, Jie KE, Emans ME, et al. Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. J Nephrol. 2010;23:363-368.
19. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol. 1989;17:10-16.
20. Clark DA, Dessypris EN. Effects of recombinant erythropoietin on murine megakaryocytic colony formation in vitro. J Lab Clin Med. 1986;108:423-429.
21. Nagasawa T, Neichi T, Satoh K, Nakazawa M, Abe T. In vitro regulatory mechanisms for cytoplasmic maturation of murine megakaryocytes derived from colony-forming units megakaryocyte (CFU-M). Exp Hematol. 1988;16:667-673.
22. Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol. 2008;21:543-549.
23. Samtleben W, Baldamus CA, Bommer J, Fassbinder W, Nonnast-Daniel B, Gurland HJ. Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol. 1988;66:114-122.
24. Buemi M, Marino D, Marino MT, et al. Does erythropoietin augment the Ca(2+)-mediated K+ flow into the red blood cells in normotensive and hypertensive subjects? Nephron. 1991;59:343-344.
25. Buemi M, Allegra A, Marino D, et al. Eritropoietina ricombinante ed ipertensione arteriosa. Giorn It di Nefrol. 1991;8:155-160.
26. Buemi M, Allegra A, Aloisi C, et al. L'ipertensione arteriosa ricombinante nei pazienti uremici. European Meeting on Cardionephrology, Assisi, Italy, 11-13 April 1991.
27. Buemi M, Allegra A, Laganà A, et al. Is erythropoietin-induced hypertension a phenomenon due to the intracellular Ca++ mobilisation? Int Angiol. 1994;13:75-77.
28. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A. 1988;85:6142-6146.
29. Lafferty HM, Garcia DL, Rennke HG, Troy JL, Anderson S, Brenner BM. Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension. J Am Soc Nephrol. 1991;1:1180-1185.
30. Lafferty HM, King AJ, Troy JL. Normalization of the renal hemodynamic abnormalities of early diabetes in the anemic rat. Kidney Int. 1990;37:511.
31. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with endstage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000.
32. Casati S, Passerini P, Campise MR, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed). 1987;295:1017-1020.
33. Schaefer RM, Leschke M, Strauer BE, Heidland A. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol. 1988;8:449-453.
34. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet. 1988;1:97-100.
35. Allegra A, Buemi M, Corica F, Giacobbe MS, Frisina N, Ceruso D. [Erythropoietin: current aspects and prospects] [article in Italian]. Recenti Prog Med. 1989;80:531-536.
36. Tu Q, Zhang QX. Effects of recombinant erythropoietin on terminal cytoplasmic maturation of megakaryocytes and thrombopoiesis. Sheng Li Xue Bao. 1990;42:363-367.
37. Sharpe PC, Desai ZR, Morris TC. Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol. 1994;47:159-161.
38. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
39. Zwaginga JJ. Hemodialysis, erythropoietin and megakaryocytopoiesis: factors in uremic thrombocytopathy and thrombophilia. J Thromb Haemost. 2004;2:1272-1274.
40. Ponticelli C, Casati S. Correction of anaemia with recombinant human erythropoietin. Nephron. 1989;52:201-208.
41. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
42. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
43. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
44. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif. 2010;29:86-92.